The Asia Pacific Apheresis Market is expected to witness market growth of 8.5% CAGR during the forecast period (2022-2028).
Stem cells, which develop in the bone marrow as immature cells, can mature into red blood cells, white blood cells, or platelets. Patients with certain types of blood cancers, such as leukemia, multiple myeloma, and lymphoma, can have their stem cells harvested by apheresis and then returned after chemotherapy or other treatments. The patient is first provided a growth factor medication to boost the number of stem cells, which are then differentiated via leukapheresis while the remaining blood is returned to the patient. The gathered stem cells are frozen and preserved until the patient's chemotherapy or radiation treatments are finished.
Plasmapheresis is the procedure of partitioning plasma from blood, typically through centrifugation or filtration. Plasmapheresis is frequently performed on healthy persons to obtain plasma only, which is then used for fluid resuscitation to patients or as an origin for plasma speculative planning and preparation such as albumin, clot formation factor derived from plasma grouped from large numbers of donated units.
As Japan's ageing population necessitates more blood, young students make up a lower and less percentage of the donor pool. It is critical to choose eligible donors in order to provide a safe and long-term blood supply. The goal of this study is to determine the prevalence of donor deferral, the reasons for deferral, and the features of delayed Japanese students.
During the 12-month period, 24,778 of the 231,361 visitors were students. Of these, 19,193 sought donations, while 5,585 were turned down. The main reasons for interim postponement were low hemoglobin, survey interview decisions, and medicine. Low hemoglobin was linked to age, sex, and blood center location; medication-based deferral was linked to donation history and blood center location.
Researchers used two separate full samples from Guangzhou and Chengdu, each containing 135,851 and 82,129 plateletpheresis donors between October 2012 and September 2019. Gender, blood donation history, and birth year were grouped over 14 cross-sections (each with a 6-month interval) to produce a total of 24 cohort groups (14 24 = 336 cohorts, i.e., cells) with common variables. The average apheresis platelet counts per donor in each cell were the result.
The China market dominated the Asia Pacific Apheresis Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $315.8 million by 2028. The Japan market is anticipated to grow at a CAGR of 7.8% during (2022-2028). Additionally, The India market is expected to showcase a CAGR of 9.2% during (2022-2028).
Based on Procedure, the market is segmented into Donor/Automated and Therapeutic. Based on Product, the market is segmented into Disposable & Reagents, Devices, and Software. Based on Method, the market is segmented into Centrifugation, Membrane Separation, and Selective Adsorption. Based on End User, the market is segmented into Blood Centers, Hospitals, and Others. Based on Component, the market is segmented into Plasma (Plasmapheresis), Platelets (Plateletpheresis), Leukocytes (Leukapheresis or leukopheresis), Lymphocytes (Lymphopheresis or lymphapheresis), and RBC's (Erythropheresis). Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Haemonetics Corporation, Fresenius SE & Co. KGaA, Terumo Corporation, Asahi Kasei Medical Co., Ltd., Kaneka Corporation, Cerus Corporation, B. Braun Melsungen AG, Nikkiso Co., Ltd., Charles River Laboratories International, Inc., and SB Kawasumi Laboratories, Inc.
By Procedure
Stem cells, which develop in the bone marrow as immature cells, can mature into red blood cells, white blood cells, or platelets. Patients with certain types of blood cancers, such as leukemia, multiple myeloma, and lymphoma, can have their stem cells harvested by apheresis and then returned after chemotherapy or other treatments. The patient is first provided a growth factor medication to boost the number of stem cells, which are then differentiated via leukapheresis while the remaining blood is returned to the patient. The gathered stem cells are frozen and preserved until the patient's chemotherapy or radiation treatments are finished.
Plasmapheresis is the procedure of partitioning plasma from blood, typically through centrifugation or filtration. Plasmapheresis is frequently performed on healthy persons to obtain plasma only, which is then used for fluid resuscitation to patients or as an origin for plasma speculative planning and preparation such as albumin, clot formation factor derived from plasma grouped from large numbers of donated units.
As Japan's ageing population necessitates more blood, young students make up a lower and less percentage of the donor pool. It is critical to choose eligible donors in order to provide a safe and long-term blood supply. The goal of this study is to determine the prevalence of donor deferral, the reasons for deferral, and the features of delayed Japanese students.
During the 12-month period, 24,778 of the 231,361 visitors were students. Of these, 19,193 sought donations, while 5,585 were turned down. The main reasons for interim postponement were low hemoglobin, survey interview decisions, and medicine. Low hemoglobin was linked to age, sex, and blood center location; medication-based deferral was linked to donation history and blood center location.
Researchers used two separate full samples from Guangzhou and Chengdu, each containing 135,851 and 82,129 plateletpheresis donors between October 2012 and September 2019. Gender, blood donation history, and birth year were grouped over 14 cross-sections (each with a 6-month interval) to produce a total of 24 cohort groups (14 24 = 336 cohorts, i.e., cells) with common variables. The average apheresis platelet counts per donor in each cell were the result.
The China market dominated the Asia Pacific Apheresis Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $315.8 million by 2028. The Japan market is anticipated to grow at a CAGR of 7.8% during (2022-2028). Additionally, The India market is expected to showcase a CAGR of 9.2% during (2022-2028).
Based on Procedure, the market is segmented into Donor/Automated and Therapeutic. Based on Product, the market is segmented into Disposable & Reagents, Devices, and Software. Based on Method, the market is segmented into Centrifugation, Membrane Separation, and Selective Adsorption. Based on End User, the market is segmented into Blood Centers, Hospitals, and Others. Based on Component, the market is segmented into Plasma (Plasmapheresis), Platelets (Plateletpheresis), Leukocytes (Leukapheresis or leukopheresis), Lymphocytes (Lymphopheresis or lymphapheresis), and RBC's (Erythropheresis). Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Haemonetics Corporation, Fresenius SE & Co. KGaA, Terumo Corporation, Asahi Kasei Medical Co., Ltd., Kaneka Corporation, Cerus Corporation, B. Braun Melsungen AG, Nikkiso Co., Ltd., Charles River Laboratories International, Inc., and SB Kawasumi Laboratories, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Procedure
- Donor/Automated
- Therapeutic
- Disposable & Reagents
- Devices
- Software
- Centrifugation
- Membrane Separation
- Selective Adsorption
- Blood Centers
- Hospitals
- Others
- Plasma (Plasmapheresis)
- Platelets (Plateletpheresis)
- Leukocytes (Leukapheresis or leukopheresis)
- Lymphocytes (Lymphopheresis or lymphapheresis)
- RBC's (Erythropheresis)
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Haemonetics Corporation
- Fresenius SE & Co. KGaA
- Terumo Corporation
- Asahi Kasei Medical Co., Ltd
- Kaneka Corporation
- Cerus Corporation
- B.Braun Melsungen AG
- Nikkiso Co., Ltd
- Charles River Laboratories International, Inc.
- SB Kawasumi Laboratories, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Asia Pacific Apheresis Market by Procedure
Chapter 5. Asia Pacific Apheresis Market by Product
Chapter 6. Asia Pacific Apheresis Market by Method
Chapter 7. Asia Pacific Apheresis Market by End User
Chapter 8. Asia Pacific Apheresis Market by Component
Chapter 9. Asia Pacific Apheresis Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Haemonetics Corporation
- Fresenius SE & Co. KGaA
- Terumo Corporation
- Asahi Kasei Medical Co., Ltd
- Kaneka Corporation
- Cerus Corporation
- B. Braun Melsungen AG
- Nikkiso Co., Ltd
- Charles River Laboratories International, Inc.
- SB Kawasumi Laboratories, Inc.
Methodology
LOADING...
